COVID-19后遗症心肌损伤的诊疗进展

doi:10.12114/j.issn.1007-9572.2024.0247

中国全科医学 ›› 2026, Vol. 29 ›› Issue (18): 2585-2592.DOI: 10.12114/j.issn.1007-9572.2024.0247

所属专题： COVID-19疫情防控研究

• 综述与专论 • 上一篇

COVID-19后遗症心肌损伤的诊疗进展

陈义萍¹^,², 张剑梅²^,^*(), 厉彦虎³, 李睿⁴, 张瑞平², 杨萍⁴

1．100084　北京市，北京体育大学
2．100061　北京市，国家体育总局运动医学研究所体育医院心血管康复科
3．100061　北京市，国家体育总局运动医学研究所运动健康医学研究中心
4．610041　四川省成都市，成都体育学院

收稿日期:2025-01-17 修回日期:2025-08-08 出版日期:2026-06-20 发布日期:2024-07-22
通讯作者: 张剑梅
作者贡献：
陈义萍负责文章的构思与设计、文献整理及论文撰写；张剑梅负责文章构思与修订，对文章整体负责；厉彦虎、李睿、张瑞平、杨萍负责论文修订。
基金资助:
国家重点研发计划项目(2022YFC2010200)

Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury

CHEN Yiping¹^,², ZHANG Jianmei²^,^*(), LI Yanhu³, LI Rui⁴, ZHANG Ruiping², YANG Ping⁴

1. Beijing Sport University, Beijing 100084, China
2. Deparment of Cardiovascular Rehabilitation, Sports Hospital of NRISM, Beijing 100061, China
3. Sports Health Medicine Research Center, National Research Institute of Sports Medicine, Beijing 100061, China
4. Chengdu Sport University, Chengdu 610041, China

Received:2025-01-17 Revised:2025-08-08 Published:2026-06-20 Online:2024-07-22
Contact: ZHANG Jianmei

摘要/Abstract

摘要： COVID-19后遗症（PCC）心肌损伤患者表现出心悸、胸闷、胸痛等多种心脏相关症状，但没有心血管疾病的客观证据。近年来，PCC心肌损伤作为一种新发病症，诊断和治疗缺乏循证医学证据支持。临床对该病症的诊疗经验不足，易导致患者病情迁延不愈，生活质量下降。因此，本文重点探讨PCC心肌损伤的诊断、临床治疗与康复的最新研究进展，提高临床工作者对这一疾病的认识。

关键词: 新型冠状病毒感染, COVID-19后遗症, 心肌疾病, 诊断与治疗, 综述

Abstract:

Patients with post-COVID-19 condition (PCC) of myocardial injury may exhibit a variety of cardiac-related symptoms, such as palpitations, chest distress, chest pain, without objective evidence of cardiovascular disease. In recent years, PCC of myocardial injury, as a newly emerging condition, lacks evidence-based medical evidence to support its diagnosis and treatment. Insufficient clinical experience in the diagnosis and treatment can easily lead to prolonged illness and decreased quality of life in patients. Therefore, this article focuses on the latest research progress in the diagnosis, clinical treatment, and rehabilitation of PCC of myocardial injury and improves the knowledge of clinical workers about this disease.

Key words: COVID-19, Post-COVID-19 condition, Cardiomyopathies, Diagnosis and treatment, Review

陈义萍,张剑梅,厉彦虎,等. COVID-19后遗症心肌损伤的诊疗进展[J]. 中国全科医学, 2026, 29(18): 2585-2592. DOI: 10.12114/j.issn.1007-9572.2024.0247.
CHEN Yiping,ZHANG Jianmei,LI Yanhu, et al. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury[J]. Chinese General Practice, 2026, 29(18): 2585-2592. DOI: 10.12114/j.issn.1007-9572.2024.0247.

参考文献 71

[1]	SORIANO J B, MURTHY S, MARSHALL J C, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus[J]. Lancet Infect Dis, 2022, 22(4): e102-e107. DOI: 10.1016/S1473-3099(21)00703-9.
[2]	WRITING COMMITTEE, GLUCKMAN T J, BHAVE N M, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 79(17): 1717-1756. DOI: 10.1016/j.jacc.2022.02.003.
[3]	李发久, 朱紫阳, 陈实, 等. 新型冠状病毒肺炎相关心肌损伤的临床观察[J]. 武汉大学学报(医学版), 2021, 42(5): 698-703. DOI: 10.14188/j.1671-8852.2020.0375.
[4]	ANUPAMA B K, CHAUDHURI D. A review of acute myocardial injury in coronavirus disease 2019[J]. Cureus, 2020, 12(6): e8426. DOI: 10.7759/cureus.8426.
[5]	SHI S B, QIN M, SHEN B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5(7): 802-810. DOI: 10.1001/jamacardio.2020.0950.
[6]	GIUSTINO G, CROFT L B, STEFANINI G G, et al. Characterization of myocardial injury in patients with COVID-19[J]. J Am Coll Cardiol, 2020, 76(18): 2043-2055. DOI: 10.1016/j.jacc.2020.08.069.
[7]	SANDOVAL Y, JANUZZI J L Jr, JAFFE A S. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week[J]. J Am Coll Cardiol, 2020, 76(10): 1244-1258. DOI: 10.1016/j.jacc.2020.06.068.
[8]	GUO T, FAN Y Z, CHEN M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019(COVID-19)[J]. JAMA Cardiol, 2020, 5(7): 811-818. DOI: 10.1001/jamacardio.2020.1017.
[9]	WANG C W, CHUANG H C, TAN T H. ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification[J]. J Biomed Sci, 2023, 30(1): 71. DOI: 10.1186/s12929-023-00965-9.
[10]	HUYNH T V, RETHI L, LEE T W, et al. Spike protein impairs mitochondrial function in human cardiomyocytes: mechanisms underlying cardiac injury in COVID-19[J]. Cells, 2023, 12(6): 877. DOI: 10.3390/cells12060877.
[11]	BAILEY A L, DMYTRENKO O, GREENBERG L, et al. SARS-CoV-2 infects human EngineeredHeart tissues and models COVID-19 myocarditis[J]. JACC Basic Transl Sci, 2021, 6(4): 331-345. DOI: 10.1016/j.jacbts.2021.01.002.
[12]	GYÖNGYÖSI M, ALCAIDE P, ASSELBERGS F W, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases[J]. Cardiovasc Res, 2023, 119(2): 336-356. DOI: 10.1093/cvr/cvac115.
[13]	WRITING COMMITTEE, GLUCKMAN T J, BHAVE N M, et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American college of cardiology solution set oversight committee[J]. J Am Coll Cardiol, 2022, 79(17): 1717-1756. DOI: 10.1016/j.jacc.2022.02.003.
[14]	LAI C C, HSU C K, YEN M Y, et al. Long COVID: an inevitable sequela of SARS-CoV-2 infection[J]. J Microbiol Immunol Infect, 2023, 56(1): 1-9. DOI: 10.1016/j.jmii.2022.10.003.
[15]	国家老年医学中心, 中国老年医学学会心电与心功能分会, 北京医学会心血管病学分会影像学组, 等. 新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识(第二版)[J]. 中国全科医学, 2023, 26(14): 1692-1702. DOI: 10.12114/j.issn.1007-9572.2023.0083.
[16]	KNIGHT D S, KOTECHA T, RAZVI Y, et al. COVID-19: myocardial injury in survivors[J]. Circulation, 2020, 142(11): 1120-1122. DOI: 10.1161/CIRCULATIONAHA.120.049252.
[17]	HUANG L, ZHAO P J, TANG D Z, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging[J]. JACC Cardiovasc Imaging, 2020, 13(11): 2330-2339. DOI: 10.1016/j.jcmg.2020.05.004.
[18]	KAPUSTA J, BABICKI M, PIENIAWSKA-ŚMIECH K, et al. Clinical and electrocardiographic correlates of myocardial dysfunction after COVID-19 in nonhospitalised patients in long-term follow-up. Data from the Polish long-covid cardiovascular study[J]. J Med Virol, 2023, 95(12): e29331. DOI: 10.1002/jmv.29331.
[19]	TAMAN, MAGEED N, ELMORSY M, et al. Heart rate variability as an indicator of COVID-19 induced myocardial injury: a retrospective cohort study[J]. BMC Anesthesiol, 2023, 23(1): 17. DOI: 10.1186/s12871-023-01975-8.
[20]	MOOREN F C, BÖCKELMANN I, WARANSKI M, et al. Autonomic dysregulation in long-term patients suffering from Post-COVID-19 Syndrome assessed by heart rate variability[J]. Sci Rep, 2023, 13(1): 15814. DOI: 10.1038/s41598-023-42615-y.
[21]	ALTERSBERGER M, GOLIASCH G, KHAFAGA M, et al. Echocardiography and lung ultrasound in long COVID and post-COVID syndrome, a review document of the Austrian society of pneumology and the Austrian society of ultrasound in medicine[J]. J Ultrasound Med, 2023, 42(2): 269-277. DOI: 10.1002/jum.16068.
[22]	YANG H, NEGISHI K, WANG Y, et al. Echocardiographic screening for non-ischaemic stage B heart failure in the community[J]. Eur J Heart Fail, 2016, 18(11): 1331-1339. DOI: 10.1002/ejhf.643.
[23]	LUETKENS J A, SCHLESINGER-IRSCH U, KUETTING D L, et al. Feature-tracking myocardial strain analysis in acute myocarditis: diagnostic value and association with myocardial oedema[J]. Eur Radiol, 2017, 27(11): 4661-4671. DOI: 10.1007/s00330-017-4854-4.
[24]	GHERBESI E, BERGAMASCHI L, CUSMANO I, et al. The usefulness of speckle tracking echocardiography in identifying subclinical myocardial dysfunction in young adults recovered from mild COVID-19[J]. Echocardiography, 2022, 39(9): 1190-1197. DOI: 10.1111/echo.15431.
[25]	FU H, ZHANG N, ZHENG Y L, et al. Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients[J]. J Infect, 2021, 83(1): 119-145. DOI: 10.1016/j.jinf.2021.04.016.
[26]	国家心血管病专业质控中心心血管影像质控专家工作组. 中国心血管影像技术应用现状调查与医疗质量报告[J]. 中国循环杂志, 2020, 35(7): 625-633. DOI: 10.3969/j.issn.1000-3614.2020.07.001.
[27]	CROSIER R, KAFIL T S, PATERSON D I. Imaging for cardiovascular complications of COVID-19: cardiac manifestations in context[J]. Can J Cardiol, 2023, 39(6): 779-792. DOI: 10.1016/j.cjca.2023.01.022.
[28]	WANG R S, LOSCALZO J. Repurposing drugs for the treatment of COVID-19 and its cardiovascular manifestations[J]. Circ Res, 2023, 132(10): 1374-1386. DOI: 10.1161/CIRCRESAHA.122.321879.
[29]	FUNG K W, BAYE F, BAIK S H, et al. Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients[J]. JAMA Intern Med, 2023, 183(12): 1404-1406. DOI: 10.1001/jamainternmed.2023.5099.
[30]	ClinicalTrials.gov. RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms [EB/OL]. [2024-08-08].
[31]	ClinicalTrials.gov. imPROving Quality of LIFe In the Long COVID Patient[EB/OL]. [2024-08-08].
[32]	HE W, XU K, NI L, et al. Myocardial injury and related mortality in hospitalized patients with COVID-19 during the Omicron pandemic: new perspectives and insights[J]. Virol Sin, 2023, 38(6): 940-950. DOI: 10.1016/j.virs.2023.10.005.
[33]	ZHENG Y Y, MA Y T, ZHANG J Y, et al. COVID-19 and the cardiovascular system[J]. Nat Rev Cardiol, 2020, 17(5): 259-260. DOI: 10.1038/s41569-020-0360-5.
[34]	ClinicalTrials.gov. Stratified Medicine of Eplerenone in Acute MI/Injury[EB/OL]. [2024-08-08].
[35]	PETCHERSKI A, SHARMA M, SATTA S, et al. Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models[J]. bioRxiv, 2022: 2022.02.22.481100. DOI: 10.1101/2022.02.22.481100.
[36]	BARLETTA M A, MARINO G, SPAGNOLO B, et al. Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome[J]. Clin Exp Med, 2023, 23(3): 667-678. DOI: 10.1007/s10238-022-00871-8.
[37]	BOJKOVA D, KLANN K, KOCH B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets[J]. Nature, 2020, 583(7816): 469-472. DOI: 10.1038/s41586-020-2332-7.
[38]	JIRAK P, VAN ALMSICK V, DIMITROULIS D, et al. Dexamethasone improves cardiovascular outcomes in critically ill COVID-19, a real world scenario multicenter analysis[J]. Front Med, 2022, 9: 808221. DOI: 10.3389/fmed.2022.808221.
[39]	CHOU C H, HUNG C S, LIAO C W, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis[J]. Cardiovasc Res, 2018, 114(5): 690-702. DOI: 10.1093/cvr/cvy013.
[40]	MARIETTE X, HERMINE O, THARAUX P L, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial[J]. JAMA Intern Med, 2021, 181(9): 1241-1243. DOI: 10.1001/jamainternmed.2021.2209.
[41]	LEISMAN D E, RONNER L, PINOTTI R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes[J]. Lancet Respir Med, 2020, 8(12): 1233-1244. DOI: 10.1016/S2213-2600(20)30404-5.
[42]	CAVALLI G, LUCA G D, CAMPOCHIARO C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study[J]. Lancet Rheumatol, 2020, 2(6): e325-e331. DOI: 10.1016/S2665-9913(20)30127-2.
[43]	DIXON S J, LEMBERG K M, LAMPRECHT M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. DOI: 10.1016/j.cell.2012.03.042.
[44]	YANG L, WU Y Y, JIN W D, et al. The potential role of ferroptosis in COVID-19-related cardiovascular injury[J]. Biomedecine Pharmacother, 2023, 168: 115637. DOI: 10.1016/j.biopha.2023.115637.
[45]	HAN Y L, ZHU J J, YANG L L, et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells[J]. Circ Res, 2022, 130(7): 963-977. DOI: 10.1161/CIRCRESAHA.121.320518.
[46]	LIBBY P, LÜSCHER T. COVID-19 is, in the end, an endothelial disease[J]. Eur Heart J, 2020, 41(32): 3038-3044. DOI: 10.1093/eurheartj/ehaa623.
[47]	KELL D B, LAUBSCHER G J, PRETORIUS E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications[J]. Biochem J, 2022, 479(4): 537-559. DOI: 10.1042/BCJ20220016.
[48]	SYKES R A, NEVES K B, ALVES-LOPES R, et al. Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy[J]. Eur Heart J Cardiovasc Pharmacother, 2023, 9(4): 371-386. DOI: 10.1093/ehjcvp/pvad025.
[49]	ZIMMERMANN P, SOURIJ H, ABERER F, et al. SGLT2 inhibitors in long COVID syndrome: is there a potential role?[J]. J Cardiovasc Dev Dis, 2023, 10(12): 478. DOI: 10.3390/jcdd10120478.
[50]	HUANG C L, HUANG L X, WANG Y M, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study[J]. Lancet, 2023, 401(10393): e21-e33. DOI: 10.1016/S0140-6736(23)00810-3.
[51]	SKJØRTEN I, ANKERSTJERNE O A W, TREBINJAC D, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation[J]. Eur Respir J, 2021, 58(2): 2100996. DOI: 10.1183/13993003.00996-2021.
[52]	BUCKLEY B J R, HARRISON S L, FAZIO-EYNULLAYEVA E, et al. Exercise rehabilitation associates with lower mortality and hospitalisation in cardiovascular disease patients with COVID-19[J]. Eur J Prev Cardiol, 2022, 29(1): e32-e34. DOI: 10.1093/eurjpc/zwaa135.
[53]	MARON B J, UDELSON J E, BONOW R O, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American heart association and American college of cardiology[J]. Circulation, 2015, 132(22): e273-e280. DOI: 10.1161/CIR.0000000000000239.
[54]	SÁNCHEZ-GARCÍA J C, REINOSO-COBO A, PIQUERAS-SOLA B, et al. Long COVID and physical therapy: a systematic review[J]. Diseases, 2023, 11(4): 163. DOI: 10.3390/diseases11040163.
[55]	VAN DE VOOREN H, GADEMAN M G, SWENNE C A, et al. Baroreflex sensitivity, blood pressure buffering, and resonance: what are the links? Computer simulation of healthy subjects and heart failure patients[J]. J Appl Physiol, 2007, 102(4): 1348-1356. DOI: 10.1152/japplphysiol.00158.2006.
[56]	CORRADO J, IFTEKHAR N, HALPIN S, et al. HEART rate variability biofeedback for long COVID dysautonomia (HEARTLOC): results of a feasibility study[J]. Adv Rehabil Sci Pract, 2024, 13: 27536351241227261. DOI: 10.1177/27536351241227261.
[57]	BRAWNER C A, EHRMAN J K, BOLE, et al. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019[J]. Mayo Clin Proc, 2021, 96(1): 32-39. DOI: 10.1016/j.mayocp.2020.10.003.
[58]	SCURATI R, PAPINI N, GIUSSANI P, et al. The challenge of long COVID-19 management: from disease molecular hallmarks to the proposal of exercise as therapy[J]. Int J Mol Sci, 2022, 23(20): 12311. DOI: 10.3390/ijms232012311.
[59]	MARTINEZ M W, TUCKER A M, BLOOM O J, et al. Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening[J]. JAMA Cardiol, 2021, 6(7): 745-752. DOI: 10.1001/jamacardio.2021.0565.
[60]	JIMENO-ALMAZÁN A, FRANCO-LÓPEZ F, BUENDÍA-ROMERO Á, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial[J]. Scand J Med Sci Sports, 2022, 32(12): 1791-1801. DOI: 10.1111/sms.14240.
[61]	BARBARA C, CLAVARIO P, MARZO V D, et al. Effects of exercise rehabilitation in patients with long coronavirus disease 2019[J]. Eur J Prev Cardiol, 2022, 29(7): e258-260. DOI: 10.1093/eurjpc/zwac019.
[62]	MOOREN J M, GARBSCH R, SCHÄFER H, et al. Medical rehabilitation of patients with post-COVID-19 syndrome-a comparison of aerobic interval and continuous training[J]. J Clin Med, 2023, 12(21): 6739. DOI: 10.3390/jcm12216739.
[63]	MCGREGOR G, POWELL R, BEGG B, et al. High-intensity interval training in cardiac rehabilitation: a multi-centre randomized controlled trial[J]. Eur J Prev Cardiol, 2023, 30(9): 745-755. DOI: 10.1093/eurjpc/zwad039.
[64]	CASONATTO J, GOESSLER K F, CORNELISSEN V A, et al. The blood pressure-lowering effect of a single bout of resistance exercise: a systematic review and meta-analysis of randomised controlled trials[J]. Eur J Prev Cardiol, 2016, 23(16): 1700-1714. DOI: 10.1177/2047487316664147.
[65]	MARZOLINI S, OH P I, BROOKS D. Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: a meta-analysis[J]. Eur J Prev Cardiol, 2012, 19(1): 81-94. DOI: 10.1177/1741826710393197.
[66]	WILLIAMS M A, HASKELL W L, ADES P A, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism[J]. Circulation, 2007, 116(5): 572-584. DOI: 10.1161/CIRCULATIONAHA.107.185214.
[67]	SCHMIDT T, BJARNASON-WEHRENS B, ZACHER J, et al. Sports, myocarditis and COVID-19: diagnostics, prevention and return-to-play strategies[J]. Int J Sports Med, 2022, 43(13): 1097-1105. DOI: 10.1055/a-1810-5314.
[68]	PRICE K J, GORDON B A, BIRD S R, et al. A review of guidelines for cardiac rehabilitation exercise programmes: is there an international consensus?[J]. Eur J Prev Cardiol, 2016, 23(16): 1715-1733. DOI: 10.1177/2047487316657669.
[69]	RONG J, LI J, JING F S, et al. Efficacy of Baduanjin exercise for rehabilitation after COVID-19: a protocol for systematic review and meta-analysis[J]. Medicine, 2021, 100(24): e26366. DOI: 10.1097/MD.0000000000026366.
[70]	SAENGSIN K, SITTIWANGKUL R, CHATTIPAKORN S C, et al. Hydrogen therapy as a potential therapeutic intervention in heart disease: from the past evidence to future application[J]. Cell Mol Life Sci, 2023, 80(6): 174. DOI: 10.1007/s00018-023-04818-4.
[71]	LEITMAN M, FUCHS S, TYOMKIN V, et al. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial[J]. Sci Rep, 2023, 13(1): 9473. DOI: 10.1038/s41598-023-36570-x.

COVID-19后遗症心肌损伤的诊疗进展

Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 71

相关文章 15

编辑推荐

Metrics

留言

[1]	冯宇茜, 王津津, 蔡一, 朱润芝, 朱勤. 乳酸化修饰在肾脏疾病中的研究进展[J]. 中国全科医学, 2026, 29(21): 3056-3063.
[2]	李文萍, 陈建华, 许家培, 金雪, 潘子涵, 迟春花. 数智化健康管理平台赋能社区老年人健康服务的范围综述[J]. 中国全科医学, 2026, 29(21): 2938-2949.
[3]	程玉, 韩士尧, 孙平, 向娟, 杨辉, 李东泽, 郑莉, 廖晓阳. 慢性病管理中的社会经济与人口学挑战分析[J]. 中国全科医学, 2026, 29(20): 2800-2807.
[4]	张明悦, 侯艳. 呼出气、肺泡气一氧化氮在间质性肺疾病中的研究进展[J]. 中国全科医学, 2026, 29(18): 2571-2576.
[5]	马晓雨, 马晓梅, 武国智, 郑亚, 郭庆红. 中性粒细胞外陷阱在胃癌中的研究进展[J]. 中国全科医学, 2026, 29(17): 2425-2432.
[6]	李佳威, 葛奥淇, 高欣怡, 李娟娟, 袁蓓蓓. 医防融合的概念内涵和实现路径：一项系统综述研究[J]. 中国全科医学, 2026, 29(16): 2156-2166.
[7]	汪洋, 金花, 杨森, 杨辉, 于德华. 中国基本医疗服务功能特征及其对卫生服务结局的影响路径：一项15年的混合方法系统综述[J]. 中国全科医学, 2026, 29(16): 2140-2155.
[8]	叶鑫瑛, 殷安康, 刘定岭, 吕翔, 王逸. 按病种分值付费支付模式下综合医院全科医学科发展研究[J]. 中国全科医学, 2026, 29(11): 1378-1384.
[9]	施雨峰, 卢晨霞, 吕安淇, 李晓东. 基于肠-肝轴理论探讨韦荣球菌属与肝脏疾病关系的研究进展[J]. 中国全科医学, 2026, 29(11): 1488-1496.
[10]	孙宇辰, 石雅馨, 师伟. 经血源性干细胞联合补肾活血类中药治疗子宫内膜功能减退类疾病的研究进展[J]. 中国全科医学, 2026, 29(11): 1481-1487.
[11]	王昱棋, 叶睿雪, 高焱, 薛凯文, 周静, 李冬霞, 郝英姿, 李晓轩, 王玉龙. 康复分级诊疗体系的国内外发展现状及应用需求探讨[J]. 中国全科医学, 2026, 29(10): 1250-1255.
[12]	焦玺同, 刘璐, 郭嘉悦, 尤莉莉. 国内外高血压数字疗法产品的应用前景及对我国的启示[J]. 中国全科医学, 2026, 29(10): 1354-1360.
[13]	杨旭, 樊洁婷, 宋红艳, 冯盼盼, 郝婧宇, 姚弥. 基层全科医生心血管疾病风险评估与沟通策略[J]. 中国全科医学, 2026, 29(10): 1294-1299.
[14]	葛奥淇, 高欣怡, 李佳威, 李娟娟, 袁蓓蓓. 基层医务人员慢性病健康行为管理能力的培训干预及其效果：系统综述及Meta分析[J]. 中国全科医学, 2026, 29(09): 1109-1120.
[15]	王晨瑜, 王晓艳, 张立秀, 王丽娜. 轻度认知障碍人群社区筛查与诊断管理策略的研究进展[J]. 中国全科医学, 2026, 29(08): 1037-1043.